A Liberian Health Care Worker with Fever

Levine, Adam C.; Shetty, Pranav; Henwood, Patricia C.; Sabeti, Pardis C.; Katz, Joel T.; Vaidya, Anand

doi:10.1056/nejmimc1414101

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown evidence of bacterial translocation across the gastrointestinal wall in EVD, leading to the risk of Gram‐negative bacteraemia . Antibiotics also provide treatment for concomitant bacterial infections common in patients with both suspected and confirmed EVD . Among antibiotics, third‐generation cephalosporins are recommended for use in empiric treatment of patients with suspected or confirmed EVD as they act against a broad range of bacterial pathogens, including Gram‐negative gastrointestinal organisms .…”

Section: Introductionmentioning

confidence: 99%

Association between treatment with oral third‐generation cephalosporin antibiotics and mortality outcomes in Ebola virus disease: a multinational retrospective cohort study

Aluisio

Perera

Yam

et al. 2020

Tropical Med Int Health

Self Cite

View full text Add to dashboard Cite

objective To evaluate the association between oral third-generation cephalosporin antibiotic treatment and mortality in Ebola virus disease (EVD).methods This retrospective cohort studied EVD-infected patients admitted to five Ebola Treatment Units in Sierra Leone and Liberia during 2014-15. Empiric treatment with cefixime 400 mg once daily for five days was the clinical protocol; however, due to resource variability, only a subset of patients received treatment. Data on sociodemographics, clinical characteristics, malaria status and Ebola viral loads were collected. The primary outcome was mortality compared between cases treated with cefixime within 48 h of admission to those not treated within 48 h. Propensity scores were derived using clinical covariates. Mortality between treated and untreated cases was compared using propensity-matched conditional logistic regression and bootstrapped log-linear regression analyses to calculate an odds ratio (OR) and relative risk (RR), respectively, with associated 95% confidence intervals (CI).results Of 424 cases analysed, 360 (84.9%) met the cefixime treatment definition. The mean age was 30.5 years and 40.3% were male. Median cefixime treatment duration was 4 days (IQR: 3, 5). Among cefixime-treated patients, mortality was 54.7% (95% CI: 49.6-59.8%) vs. 73.4% (95% CI: 61.5-82.7%) in untreated patients. In conditional logistic regression, mortality likelihood was significantly lower among cases receiving cefixime (OR = 0.48, 95% CI: 0.32-0.71; P = 0.01). In the bootstrap analysis, a non-significant risk reduction was found with cefixime treatment (RR = 0.82, 95% CI: 0.64-1.16, P = 0.11).conclusion Early oral cefixime may be associated with reduced mortality in EVD and warrants further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%